Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 randomized double-blind placebo-controlled study of rimegepant multiple-dose regimens for prevention of episodic migraine
MOH_2023-04-15_012410Phase 4Not yet recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in migraine and episodic migraine comparing Rimegepant every other day alternating with matching placebo, Rimegepant daily and Daily matching placebo (3 arms). Planned start Oct 2022; status: not yet recruiting.
02
Drugs
rimegepant
03
Conditions
migraineepisodic migraine
Beyond the preview
Go deeper on MOH_2023-04-15_012410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-15_012410.